Fennec Pharmaceuticals
FENC
22 hedge funds and large institutions have $92.2M invested in Fennec Pharmaceuticals in 2018 Q1 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 4 reducing their positions, and 2 closing their positions.
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
50% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 4
27% more capital invested
Capital invested by funds: $72.3M → $92.2M (+$19.9M)
22% more funds holding
Funds holding: 18 → 22 (+4)
2.94% more ownership
Funds ownership: 44.94% → 47.89% (+2.9%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PI
Putnam Investments
Boston,
Massachusetts
|
+$1.38M |
| 2 |
Millennium Management
New York
|
+$875K |
| 3 |
ACA
Avoro Capital Advisors
New York
|
+$630K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$536K |
| 5 |
Renaissance Technologies
New York
|
+$329K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GIM
Granahan Investment Management
Waltham,
Massachusetts
|
-$110K |
| 2 |
USAA
United Services Automobile Association
San Antonio,
Texas
|
-$66.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$9.53K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$8K |
| 5 |
Toronto Dominion Bank
Toronto, Ontario,
Ontario, Canada
|
-$1K |
FENC Hedge Fund Activity: Q1 2018 in Review
22 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in Fennec Pharmaceuticals (FENC) for Q1 2018, worth a combined $92.2M — up 27% from $72.3M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new FENC positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 4 trimmed.
The largest buyer was Putnam Investments, adding an estimated $1.38M. The largest seller was Granahan Investment Management, cutting an estimated $110K.
- 22 institutional investors held Fennec Pharmaceuticals (FENC) as of Q1 2018, up from 18 in Q4 2017.
- Funds reported $92.2M of Fennec Pharmaceuticals stock for Q1 2018, up 27% quarter-over-quarter.
- 6 funds opened new Fennec Pharmaceuticals positions in Q1 2018 and 2 closed out, a net change of +4 holders.
- The largest Fennec Pharmaceuticals buyer in Q1 2018 was Putnam Investments, an estimated $1.38M added.
- The largest Fennec Pharmaceuticals seller in Q1 2018 was Granahan Investment Management, an estimated $110K sold.
Based on aggregated 13F filings for Q1 2018.